Ratings Tasly Pharmaceutical Group Co., Ltd

Equities

600535

CNE000001C81

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
14.9 ^CNY	0.00%		-3.37%	-12.46%

Apr. 25	Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Tasly Pharmaceutical Group Returns to Profit in 2023 as Operating Income Stays Flat	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TASLY PHARMACEUTICAL GROUP CO., LTD	-12.46%	3.06B		B-
DONG-E-E-JIAO CO.,LTD.	+37.37%	6.05B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.69%	4.45B		C+
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-0.12%	3.04B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	+0.47%	2.58B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+36.06%	1.79B		-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.84%	1.66B	-	-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-10.60%	1.63B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.03%	1.54B		C-
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+36.40%	1.42B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes